2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu

Short Description:


Product Detail

Related Products

Product Tags

Related Video

Feedback (2)

Our solutions are widely regarded and trustworthy by consumers and may meet continually modifying financial and social requirements for Molecular Formula C11H8ClF3O3, Indinavir Sulfate CAS 157810-81-6, Lapatinib Ditosylate CAS 388082-78-8, Our main objectives are to provide our customers worldwide with good quality, competitive price, satisfied delivery and excellent services.
2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu Detail:

Supply With High Purity, Commercial Production

Chemical Name Olaparib
Synonyms AZD-2281; KU0059436; Lynparza; 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin
CAS Number 763113-22-0
CAT Number RF-API103
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C24H23FN4O3
Molecular Weight 434.46
Solubility Soluble in DMSO
Brand Ruifu Chemical
Item Specifications
Appearance White to Off-White Powder
Identification by 1H NMR Comply with the structure
LC-MS Comply with the structure
Purity / Analysis Method ≥99.0% (by LC-MS)
Moisture (K.F) ≤0.50%
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Heavy Metals (as Pb) ≤20ppm
Test Standard Enterprise Standard
Usage API; PARP Inhibitor

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

1

Olaparib (CAS: 763113-22-0), a highly potent and selective PARP-inhibitor. In December 19, 2014, the FDA approved novel anti-cancer drug Olaparib (Lynparza) for monotherapy to the patients of advanced ovarian cancer who has undergone at least 3 rounds of chemotherapy or patients of suspected BRCA mutations. At the same time, FDA approved the quantitation and classification of diagnostic kits for the detection of mutations in BRCA1 and BRCA2, BRACAnalysis CDx. Olaparib is the first PARP inhibitor drugs which has been approved by FDA. In February 2, 2015, the European Union Food and Drug Administration (EMA) also approved Olaparib to enter into market in the 28 countries of European Union including Iceland, Liechtenstein and Norway. But the indications of EMA and FDA approved are slightly different; the former is for the BRCA gene mutation cases, and also for the maintenance therapy for patients of advanced epithelial ovarian cancer who has previously received platinum-containing chemotherapy drugs and exhibit response and subject to recurrence.


Product detail pictures:

2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu detail pictures


Related Product Guide:

We consistently execute our spirit of ''Innovation bringing progress, Highly-quality ensuring subsistence, Administration advertising and marketing gain, Credit history attracting buyers for 2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu , The product will supply to all over the world, such as: Madrid, Uruguay, Doha, we are sincerely hope to establish one good long term business relationship with your esteemed company thought this opportunity, based on equal, mutual beneficial and win win business from now till the future.
  • The product classification is very detailed that can be very accurate to meet our demand, a professional wholesaler.
    5 Stars By Anna from Portugal - 2018.11.11 19:52
    Timely delivery, strict implementation of the contract provisions of the goods, encountered special circumstances, but also actively cooperate, a trustworthy company!
    5 Stars By Jo from Portland - 2018.12.28 15:18
    Write your message here and send it to us